Stephen R.D. Johnston

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

Tim Eisen, Chris Boshoff, Ian Mak et al. · British Journal of Cancer · 2000 · 341 citations · Full text

High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Alex Pearson, Elizabeth Smyth, Irina S. Babina et al. · Cancer Discovery · 2016 · 259 citations · Full text

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

Stephen R.D. Johnston, Tamas Hickish, Stephen Houston et al. · Journal of Clinical Oncology · 2003 · 196 citations

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Stephen R.D. Johnston, Biao Lü, Gary K. Scott et al. · PubMed · 1999 · 155 citations

Tumor Biology, Transcriptional Regulation, Systems Biology +15

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling

L-A Martin, Sunil Pancholi, Christina M.W. Chan et al. · Endocrine Related Cancer · 2005 · 82 citations · Full text